110 related articles for article (PubMed ID: 30885341)
1. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC;
Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341
[TBL] [Abstract][Full Text] [Related]
2. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
Derks JL; Leblay N; Thunnissen E; van Suylen RJ; den Bakker M; Groen HJM; Smit EF; Damhuis R; van den Broek EC; Charbrier A; Foll M; McKay JD; Fernandez-Cuesta L; Speel EM; Dingemans AC;
Clin Cancer Res; 2018 Jan; 24(1):33-42. PubMed ID: 29066508
[No Abstract] [Full Text] [Related]
3. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y
Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor.
Li M; Zhang Y; Zhou P; Miao Y; Li S; Jiang L
Lung Cancer; 2024 Jun; 192():107825. PubMed ID: 38795461
[TBL] [Abstract][Full Text] [Related]
5. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
Burns L; Tukachinsky H; Raskina K; Huang RSP; Schrock AB; Sands J; Kulke MH; Oxnard GR; Tapan U
Lung Cancer; 2024 Feb; 188():107454. PubMed ID: 38159439
[TBL] [Abstract][Full Text] [Related]
6. Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
Wang H; Yan L; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Lin D
Hum Pathol; 2023 Dec; 142():81-89. PubMed ID: 37742943
[TBL] [Abstract][Full Text] [Related]
7. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
Naidoo J; Santos-Zabala ML; Iyriboz T; Woo KM; Sima CS; Fiore JJ; Kris MG; Riely GJ; Lito P; Iqbal A; Veach S; Smith-Marrone S; Sarkaria IS; Krug LM; Rudin CM; Travis WD; Rekhtman N; Pietanza MC
Clin Lung Cancer; 2016 Sep; 17(5):e121-e129. PubMed ID: 26898325
[TBL] [Abstract][Full Text] [Related]
8. Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype.
Hermans BCM; Derks JL; Groen HJM; Stigt JA; van Suylen RJ; Hillen LM; van den Broek EC; Speel EJM; Dingemans AC
Endocr Connect; 2019 Dec; 8(12):1600-1606. PubMed ID: 31751303
[TBL] [Abstract][Full Text] [Related]
9. TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection.
Miyagawa-Hayashino A; Okada S; Takeda-Miyata N; Takashima Y; Yamada T; Takemura Y; Uchino J; Inoue M; Takayama K; Konishi E
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):313-320. PubMed ID: 33031101
[TBL] [Abstract][Full Text] [Related]
10. Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments.
Yoshimura M; Seki K; Bychkov A; Fukuoka J
Front Oncol; 2021; 11():671799. PubMed ID: 33968782
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous regression of recurrent pulmonary large cell neuroendocrine carcinoma with alteration of PD-L1 expression after surgical resection: A case report.
Hong G; Chung C; Park D; Lee SI; Lee JE; Kang DH
Thorac Cancer; 2024 Jan; 15(3):266-270. PubMed ID: 38057657
[TBL] [Abstract][Full Text] [Related]
12. Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature.
Zhu Z; Liu Y; Xu H; Ning H; Xia Y; Shen L
J Cardiothorac Surg; 2023 Aug; 18(1):254. PubMed ID: 37653509
[TBL] [Abstract][Full Text] [Related]
13. New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management.
Derks JL; Leblay N; Lantuejoul S; Dingemans AC; Speel EM; Fernandez-Cuesta L
J Thorac Oncol; 2018 Jun; 13(6):752-766. PubMed ID: 29454048
[TBL] [Abstract][Full Text] [Related]
14. A Semiquantitative Scoring System May Allow Biopsy Diagnosis of Pulmonary Large Cell Neuroendocrine Carcinoma.
Baine MK; Sinard JH; Cai G; Homer RJ
Am J Clin Pathol; 2020 Jan; 153(2):165-174. PubMed ID: 31593583
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary large cell neuroendocrine carcinoma (LCNEC): a population-based study addressing recent molecular-genetic advances and emerging therapeutic approaches.
Khan J; Yasinzai AQK; Matosz S; Khan M; Heneidi S; Mesa H; Chauhan A; Del Rivero J; Karim NA; Ullah A
Clin Exp Med; 2023 Nov; 23(7):3947-3955. PubMed ID: 37060529
[TBL] [Abstract][Full Text] [Related]
16. Colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: Prognostic factors and PD-L1 expression.
Ho YH; Hsu CY; Yau Li AF; Liang WY
Hum Pathol; 2024 Mar; 145():80-85. PubMed ID: 38423221
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Molecular Profiles of Large Cell Neuroendocrine Carcinoma With Potential Targets for Therapy.
Popper H; Brcic L
Front Oncol; 2021; 11():655752. PubMed ID: 34307132
[TBL] [Abstract][Full Text] [Related]
18. Does subtyping of high-grade pulmonary neuroendocrine carcinomas have an impact on therapy selection?
Popper H; Brcic L; Eidenhammer S
Transl Lung Cancer Res; 2023 Dec; 12(12):2412-2426. PubMed ID: 38205203
[TBL] [Abstract][Full Text] [Related]
19. Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix.
Cimic A; Vranic S; Arguello D; Contreras E; Gatalica Z; Swensen J
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):299-304. PubMed ID: 33208671
[TBL] [Abstract][Full Text] [Related]
20. A selected reaction monitoring mass spectrometric assessment of biomarker candidates diagnosing large-cell neuroendocrine lung carcinoma by the scaling method using endogenous references.
Fukuda T; Nomura M; Kato Y; Tojo H; Fujii K; Nagao T; Bando Y; Fehniger TE; Marko-Varga G; Nakamura H; Kato H; Nishimura T
PLoS One; 2017; 12(4):e0176219. PubMed ID: 28448532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
